

**SUMMARY SUSPENSION/NOTICE OF OPPORTUNITY FOR HEARING
TERMINAL DISTRIBUTOR OF DANGEROUS DRUGS LICENSE**

IN THE MATTER OF:

CASE NO. A-2026-0162

**Adlakha Investments Inc.
dba Grand Ave Pharmacy**
c/o Christopher Adlakha, RPh
1615 Grand Avenue Pwky, Suite 104
Pflugerville, TX 78660

License No. 02-4000424

June 1, 2026



Dear Mr. Adlakha and Grand Ave Pharmacy:

You are notified, in accordance with Section 119.07 of the Revised Code, the Ohio Board of Pharmacy (Board) hereby SUMMARILY SUSPENDS Adlakha Investments Inc. dba Grand Ave Pharmacy's license as a Terminal Distributor of Dangerous Drugs (TDDD), under authority of Sections 4729.57 and 4729.571 of the Ohio Revised Code.

Furthermore, the Board finds that based upon the facts set forth in the Allegations Section, there is clear and convincing evidence of a danger of immediate and serious harm to others due to Adlakha Investments Inc. dba Grand Ave Pharmacy's method used to possess or distribute dangerous drugs. As such, the Board summarily suspends Adlakha Investments Inc. dba Grand Ave Pharmacy's license as a Terminal Distributor of Dangerous Drugs.

JURISDICTION

1. Pursuant to Section 4729.57 of the Ohio Revised Code (ORC) and the rules adopted thereunder, the Board has the authority to suspend, revoke, restrict, limit, or refuse to grant or renew any license issued pursuant to Sections 4729.54 and 4729.55 of the ORC to practice as a TDDD in the state of Ohio. Further, pursuant to Section 4729.55(E), the Board shall refuse to issue a future license to an applicant for a TDDD if the applicant, or any agent (including any owner or responsible person) or employee of the applicant, has been found to have violated any of the specified laws identified therein or any rule of the board, absent proof of adequate safeguards assuring prevention of a recurrence of the violation. Additionally, Section 4729.57 of the Revised Code grants the Board the authority to impose a monetary penalty or forfeiture not to exceed in severity any fine designated under the Revised Code for a similar offense or \$1,000 if the acts committed have not been classified as an offense by the ORC.

2. Pursuant to Section 4729.571(A)(1) of the ORC and the rules adopted thereunder, the Board has the authority to suspend a terminal distributor's license without a hearing if it determines that there is clear and convincing evidence of a danger of immediate and serious harm to others due to the method used by the terminal distributor to possess or distribute dangerous drugs.
3. Adlakha Investments Inc. dba Grand Ave Pharmacy, located at 1615 Grand Avenue Pwky, Suite 104, Pflugerville, TX, is a licensed TDDD under license number 02-40000424. Shreya Mehta, RPh is listed as the Responsible Person and Christopher Adlakha, RPh is listed as the owner.

ALLEGATIONS

1. From on or about October 23, 2024 to on or about May 17, 2026, Adlakha Investments Inc. dba Grand Ave Pharmacy (Grand Ave Pharmacy), located at 1615 Grand Avenue Pwky, Suite 104, Pflugerville, TX, shipped unapproved compounded drugs to Ohio patients.
2. Grand Ave Pharmacy records show that between October 23, 2024 and December 17, 2025, the pharmacy dispensed 1,018 compounded prescriptions using drugs that were ineligible for compounding because they lack a United States Pharmacopeia – National Formulary (USP/NF) monograph, are not drug substances that are components of approved drugs, and do not appear on the Food and Drug Administration (FDA) approved 503A bulk drug substances list. Additionally, at least one dispensing could be classified as Biological Product, which requires an approved Biologics License Application (BLA) to compound. Grand Ave Pharmacy does not have an active approved BLA. The list of prescriptions dispensed to Ohio patients during this time period is set forth in Attachment A, attached hereto and incorporated as though fully set forth herein.
3. On or about April 15, 2026, a Board Specialist spoke with Marco Vales, a representative of Grand Ave Pharmacy. The Board Specialist informed Mr. Vales that the pharmacy was not permitted to dispense drugs in the following categories into Ohio: the FDA Bulks List - Category 2, FDA Bulks List - Category 3, drugs without a USP/NF Monograph, drugs that could be classified as Biological Product (without a BLA), and/or drugs that are not an FDA approved drug. This information was included in an April 15, 2026, Board Inspection Report; a warning requiring a written response was issued.
4. On or about May 18, 2026, a Board Specialist sent a records request for prescription dispensing records- including the shipping addresses- for drugs shipped into Ohio from December 18, 2025 to May 18, 2026.
 - a. On or about May 25, 2026, the Board received the request records; however, the records received did not include the delivery address for the prescriptions.
 - b. The records included 836 prescriptions dispensed to Ohio patients that were on the FDA Bulks List -Category 2 or FDA Bulks List - Category 3, did not have a USP/NF Monograph, could be classified as Biological Product, and/or were not an FDA approved drug, as set forth in Attachment B, attached hereto and incorporated as though fully set forth herein.

5. From on or about April 16, 2026 to May 18, 2026, 177 of the 836 prescriptions identified in Attachment B, were dispensed to Ohio patients, as set forth in Attachment C, attached hereto and incorporated as though fully set forth herein. These drugs were dispensed after April 15, 2026, when a Board Specialist notified Grand Ave Pharmacy via telephone and in writing via a written warning, that Grand Ave Pharmacy is not permitted to dispense the unapproved drugs and/or drugs containing unapproved bulk drug substances, into Ohio.

POTENTIAL VIOLATIONS OF LAW

1. Such conduct as set forth in the Allegations Section, if proven, constitutes a violation of section 3715.52 of the ORC, prohibited acts, each, a misdemeanor of the fourth degree, each punishable by a maximum penalty of \$2,000 if committed by an organization: The following acts and causing them are prohibited:
 - a. The manufacture, sale, or delivery, holding or offering for sale of any food, drug, device, or cosmetic that is adulterated¹ or misbranded,² ORC Section 3715.52(A)(1); and/or
 - b. The adulteration or misbranding of any food, drug, device, or cosmetic, ORC Section 3715.52(A)(2); and/or
 - c. The sale, delivery for sale, holding for sale, or offering for sale of any article in violation of section 3715.61 or 3715.65 of the Revised Code, ORC Section 3715.52(A)(4).
2. Such conduct as set forth in the Allegations Section, if proven, each constitutes a violation of Section 3715.65(A) of the ORC, effective April 15, 2005, No person shall sell, deliver, offer for sale, hold for sale, or give away any new drug unless an application with respect to the drug has become effective under section 505 of the "Federal Food, Drug, and Cosmetic Act," 52 Stat. 1040 (1938), 21 U.S.C.A. 301, as amended, each violation is a misdemeanor of the fourth degree, each violation punishable by a maximum penalty of \$2,000 if committed by an organization.
3. Such conduct as set forth in the Allegations Section, if proven, constitutes a violation of Section 2925.09(A) of the ORC, No person shall administer, dispense, distribute, manufacture, possess, sell, or use any drug, other than a controlled substance, that is not approved by the United States food and drug administration, or the United States department of agriculture, each a felony of the fifth degree, punishable by a maximum penalty of \$7,500 if committed by an organization.
4. Such conduct as set forth in the Allegations Section, if proven, constitutes a violation of the following sections of Rule 4729:5-2-01 of the OAC, as effective April 25, 2022, each violation punishable by a maximum penalty of \$1,000:
 - a. The responsible person to whom the terminal distributor of dangerous drugs license has been issued and all licensed health professionals on duty are responsible for compliance with all

¹ ORC Section 3715.63: When a drug or device is adulterated

² ORC Section 3715.64: Misbranded drug or device

state and federal laws, regulations, and rules governing the distribution of dangerous drugs, OAC Rule 4729:5-2-01(E)(4); and/or

- b. The responsible person shall be responsible for ensuring the terminal distributor of dangerous drugs requirements are met, including, but not limited to, the supervision and control of dangerous drugs as required in division (B) of section 4729.55 of the Revised Code, adequate safeguards as required in division (C) of section 4729.55 of the Revised Code, security and control of dangerous drugs and maintaining all drug records otherwise required, OAC Rule 4729:5-2-01(E)(6).
5. Such conduct as set forth in Allegations Section, if proven, constitutes a violation of each of the following divisions of Section 4729.57(B) of the ORC, as effective April 4, 2023, each violation punishable by a maximum penalty of \$1,000:
 - a. Violating any rule of the board, ORC Section 4729.57(B)(2); and/or
 - b. Violating any provision of this chapter, ORC Section 4729.57(B)(3); and/or
 - c. Except as provided in section 4729.89 of the Revised Code, violating any provision of the "Federal Food, Drug, and Cosmetic Act," 52 Stat. 1040 (1938), 21 U.S.C.A. 301, or Chapter 3715. of the Revised Code, ORC Section 4729.57(B)(4); and/or
 - d. Any other cause for which the board may impose discipline as set forth in rules adopted under section 4729.26 of the Revised Code, ORC Section 4729.57(B)(10).
 6. Such conduct as set forth in Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-4-01 of the OAC, as effective April 25, 2022, each violation punishable by a maximum penalty of \$1,000:
 - a. Violating any rule of the board, OAC Rule 4729:5-4-01(B)(2); and/or
 - b. Violating any provision of Chapter 4729. of the Revised Code, OAC Rule 4729:5-4-01(B)(3); and/or
 - c. Except as provided in section 4729.89 of the Revised Code, violating any provision of the "Federal Food, Drug, and Cosmetic Act," 52 Stat. 1040 (1938), 21 U.S.C.A. 301, or Chapter 3715. of the Revised Code, OAC Rule 4729:5-4-01(B)(4); and/or
 - d. Commission of an act that constitutes a misdemeanor that is related to, or committed in, the person's professional practice, OAC Rule 4729:5-4-01(B)(18); and/or
 - e. The method used by the terminal distributor to store, possess or distribute dangerous drugs poses serious harm to others, OAC Rule 4729:5-4-01(B)(23).
 7. Such conduct as set forth in the Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-8-03 of the OAC, Compliance, as effective February 1, 2022, each violation punishable by a maximum penalty of \$1,000:

- a. A nonresident terminal distributor of dangerous drug shall comply with all the statutory requirements of the state of Ohio set forth in Chapters 4729., 3719., 3715., and 2925. of the Revised Code for all drugs sold, dispensed or personally furnished into this state, unless the licensee can demonstrate that such compliance would cause the nonresident terminal distributor of dangerous drugs to violate either the statutory or regulatory requirements of the state in which it is located or federal statutory or regulatory requirements, OAC Rule 4729:5-8-03(E); and/or
 - b. A nonresident terminal distributor of dangerous drugs shall operate in compliance with all applicable laws, regulations and standards set forth by the United States food and drug administration and the United States drug enforcement administration, OAC Rule 4729:5-8-03(H); and/or
 - c. A nonresident terminal distributor of dangerous drugs shall supply, within three business days of a request, all information needed by the board of pharmacy to carry out its responsibilities as a licensing, regulatory, and drug law enforcement agency of the state of Ohio, OAC Rule 4729:5-8-03(J); and/or
 - d. A nonresident terminal distributor of dangerous drugs shall supply, within three business days of a request, all information needed by the board of pharmacy and any local, state, or federal agency to carry out its responsibilities in enforcing the federal and state laws governing the distribution of drugs in the state of Ohio, OAC Rule 4729:5-8-03(K).
8. Such conduct as set forth in Allegations Section, if proven, each constitutes a violation of the following sections of Rule 4729:5-3-14(A) of the OAC, as effective March 1, 2020, each violation punishable by a maximum penalty of \$1,000: All terminal distributors of dangerous drugs shall provide effective controls and procedures to: Ensure supervision and control of dangerous drugs, as required in division (B) of section 4729.55 of the Revised Code, and adequate safeguards to ensure that dangerous drugs are being distributed in accordance with all state and federal laws, as required in section 4729.55 of the Revised Code, OAC Rule 4729:5-3-14(A)(2).

YOU ARE FURTHER NOTIFIED, in accordance with the provisions of Chapters 119. and 4729. of the Ohio Revised Code, that you are entitled to a hearing before the Ohio Board of Pharmacy, if you request such a hearing within thirty (30) days of the date of the service of this notice.


IF YOU DESIRE A HEARING, such request shall either be mailed to the Ohio Board of Pharmacy, Attn: Legal, 77 South High Street, 17th Floor, Columbus, Ohio 43215-6126 or an e-mail request may be sent to legal@pharmacy.ohio.gov (**please note faxes will not be accepted**). **YOUR REQUEST MUST BE RECEIVED ON OR PRIOR TO THE 30TH DAY FOLLOWING THE SERVICE DATE OF THIS NOTICE.** Please note that if you submit a request via email, your request will be acknowledged within one business day of receipt. If you do not receive an acknowledgment, please contact the Board offices at 614-466-4143 and request the legal department. You may appear at such hearing in person, by your attorney, or by such other representative as is permitted to practice before the agency, or you may present your position, arguments or contentions in writing; and, at this hearing, you may also present evidence and examine any witnesses appearing for and against you. **If you are a business entity, including but not**

limited to a corporation, limited liability company, or a limited partnership, you must be represented at the hearing by an attorney licensed to practice in the state of Ohio.

YOU ARE FURTHER ADVISED that if there is no request for such a hearing received by the Board on or prior to the 30th day following the service of this notice, the Ohio Board of Pharmacy, upon consideration of the aforementioned allegations against you, may take action without such a hearing, and may adopt a final order that contains the board's findings. In the final order, the board may impose any of the sanctions listed in division RC 4729.57(A).

If you have questions regarding the Chapter 119. Administrative Hearing process, please e-mail your questions to legal@pharmacy.ohio.gov or call the Board office at 614-466-4143 and ask for the legal department.

BY ORDER OF THE OHIO BOARD OF PHARMACY



Steven W. Schierholt, Esq., Executive Director

SWS/alg/jrn

Encl: Attachment A, Attachment B, Attachment C



ATTACHMENT A

Prescriptions dispensed to Ohio patients from Grand Ave Pharmacy from on or about October 23, 2024 to on or about December 17, 2025

Row Labels	Count of Dispensed Item	Categorization
BPC 2.5 MG/ML NASAL SPRAY (15 ML)	1	Category 2
BPC-157 500mcg Capsules	40	Category 2
BPC-157 2MG/ML MDV (5mL)	58	Category 2
BPC-157 4MG/ML MDV (5mL)	262	Category 2
BPC-157/THYMOSIN-B4 500MCG/500MCG Oral Capsules	4	Category 2
Cagrilintide 5mg/mL MDV (2mL -10mg vial)	1	Not Approved
CJC 1295/IPAMORELIN 2MG-2MG/ML MDV (5mL)	109	Not Approved / Previously Category 2
CJC-1295 2MG/ML MDV (5mL)	1	Not Approved / Previously Category 2
Combo Glow Blend - BPC-157/Thymosin Beta-4/GHK-Cu 2mg-2mg-1mg/mL MDV (5mL)	38	Category 2
Combo Wolverine Pack - BPC-157/Thymosin Beta 4 3mg-3mg/mL (5mL)	83	Category 2
Dihexa 10 mg Capsules	1	Category 2
DIHEXA 20MG ORAL CAPSULES	2	Category 2
DSIP (DELTA SLEEP INDUCING) 3MG/mL (3ML MDV)	8	Category 2
Epithalon 10 mg/mL MDV (5 mL)	13	Not Approved
Foxo4-DRI 10 mg/mL MDV INJ (5mL Vial)	1	Not Approved
GHK-CU 10MG/ML MDV (5mL)	51	Category 2
Ibutamoren (MK-677) 25mg Oral Capsules	2	Category 2
Ibutamoren (MK-677) 50mg Oral Capsules	2	Category 2
IGF-LR3 200mcg/mL MDV (1mg - 5mL)	1	Biologic

Ipamorelin 2 mg/mL MDV (5mL)	9	Not Approved
Larazotide 0.5mg Oral Capsules	4	Not Approved
LL-37 1MG/ML (5ML) MDV	4	Category 2
Melanotan II 2mg/mL MDV (5mL)	5	Category 2
MOTS-C 10 MG/ML MDV (5ML)	27	Category 2
Pinealon 4mg/mL MDV (5mL)	2	Not Approved
SELANK 10MG/ML NASAL SPRAY (5ML)	13	Not Approved
SELANK 7.5MG/ML NASAL SPRAY (5ML)	9	Not Approved
SEMAX 10MG/ML NASAL SPRAY (5ML)	5	Category 2
SEMAX 7.5MG/mL NASAL SPRAY (5ML)	6	Category 2
Sermorelin/Ipamorelin 3 mg - 2 mg/mL MDV (5 mL)	10	Not Approved
SS-31 40MG/ML MDV (5ML)	8	Not Approved
Tesamorelin/Ipamorelin 3mg-0.3mg/mL MDV (10mL)	117	Not Approved
THYMOSIN ALPHA-1 3MG/ML MDV (5ML)	34	Not Approved
THYMOSIN BETA-4 3MG/ML MDV (5 mL)	65	Category 2
Thymosin Beta-4 6mg/mL MDV (5mL)	22	Category 2

ATTACHMENT B

**Prescriptions dispensed to Ohio patients from Grand Ave Pharmacy from on or about
December 18, 2025 to on or about May 18, 2026**

Dispensed Item	Count	Categorization
5-AMINO 1MQ 50MG ORAL CAPSULES	6	Unapproved
BPC-157 500mcg Capsules	9	Category 2 > April 2026 > Unapproved
BPC-157 2MG/ML MDV (5mL)	83	Category 2 > April 2026 > Unapproved
BPC-157 4MG/ML MDV (5mL)	72	Category 2 > April 2026 > Unapproved
BPC-157/THYMOSIN-B4 500MCG/500MCG Oral Capsules	1	Category 2 > April 2026 > Unapproved
Cagrilintide 5mg/mL MDV (2mL -10mg)	4	Unapproved
CJC 1295/IPAMORELIN 2MG-2MG/ML MDV (5mL)	73	Category 2 > April 2026 > Unapproved (CJC) Unapproved (Ipamorelin)
CJC-1295 2MG/ML MDV (5mL)	2	Category 2 > April 2026 > Unapproved
Combo Glow Blend - BPC-157/Thymosin Beta-4/GHK-Cu 2mg-2mg-1mg/mL MDV (5mL)	74	Category 2 > April 2026 > Unapproved
Combo Wolverine Pack - BPC-157/Thymosin Beta 4 3mg-3mg/mL MDV (5mL)	114	Category 2 > April 2026 > Unapproved
Dihexa 10 mg Capsules	1	Category 2 > April 2026 > Unapproved
DIHEXA 20MG ORAL CAPSULES	1	Category 2 > April 2026 > Unapproved
DSIP (DELTA SLEEP INDUCING) 3mg/mL MDV (3mL)	3	Category 2 > April 2026 > Unapproved
Foxo4-DRI 10 mg/mL MDV (5mL)	4	Unapproved
GHK-CU 10MG/ML MDV (5mL)	67	Category 2 > April 2026 > Unapproved
Humanin 1mg/mL MDV (10mL)	5	Unapproved
Ibutamoren (MK-677) 25mg Oral Capsules	3	Category 2
Ibutamoren (MK-677) 50mg Oral Capsules	1	Category 2
IGF-LR3 200mcg/mL MDV (1mg - 5mL)	5	Biologic
KPV 500MCG ORAL CAPSULES	5	Category 2 > April 2026 > Unapproved
Larazotide 0.5mg Oral Capsules	8	Unapproved
LL-37 1MG/ML MDV (5mL)	5	Category 2 > April 2026 > Unapproved
MOTS-C 10 MG/ML MDV (5ML)	32	Category 2 > April 2026 > Unapproved
Pinealon 4mg/mL MDV (5mL)	1	Unapproved
SELANK 10MG/ML NASAL SPRAY (5ML)	12	Category 2 > April 2026 > Unapproved
SELANK 7.5MG/ML NASAL SPRAY (5ML)	11	Category 2 > April 2026 > Unapproved
Sermorelin/Ipamorelin 3 mg - 2 mg/mL MDV (5 mL)	9	Unapproved (Ipamorelin)
SLU-PP-332 1 mg Capsules	1	Unapproved
SS-31 40MG/ML MDV (5ML)	22	Unapproved
Tesamorelin/Ipamorelin 3mg-0.3mg/mL MDV (10mL)	101	Unapproved (Ipamorelin)
THYMOSIN ALPHA-1 3MG/ML MDV (5ML)	39	Category 2 > April 2026 > Unapproved
THYMOSIN BETA-4 3MG/ML MDV (5 mL)	39	Category 2 > April 2026 > Unapproved
Thymosin Beta-4 6mg/mL MDV (5mL)	11	Category 2 > April 2026 > Unapproved
SEMAX 10MG/ML NASAL SPRAY (5ML)	5	Category 2 > April 2026 > Unapproved
SEMAX 7.5MG/mL NASAL SPRAY (5ML)	7	Category 2 > April 2026 > Unapproved
	836	

ATTACHMENT C

**Prescriptions dispensed to Ohio patients from Grand Ave Pharmacy from on or about
From on or about April 16, 2026 to May 18, 2026**

Dispensed Item	Count	Categorization
5-AMINO 1MQ 50MG ORAL CAPSULES	1	Unapproved
BPC-157 500mcg Capsules	1	Category 2 > April 2026 > Unapproved
BPC-157 2MG/ML MDV (5mL)	11	Category 2 > April 2026 > Unapproved
BPC-157 4MG/ML MDV (5mL)	18	Category 2 > April 2026 > Unapproved
CJC 1295/IPAMORELIN 2MG-2MG/ML MDV (5mL)	17	Category 2 > April 2026 > Unapproved (CJC) Unapproved (Ipamorelin)
Combo Glow Blend - BPC-157/Thymosin Beta-4/GHK-Cu 2mg-2mg-1mg/mL MDV (5mL)	21	Category 2 > April 2026 > Unapproved
Combo Wolverine Pack - BPC-157/Thymosin Beta 4 3mg-3mg/mL MDV (5mL)	25	Category 2 > April 2026 > Unapproved
DSIP (DELTA SLEEP INDUCING) 3mg/mL MDV (3mL)	1	Category 2 > April 2026 > Unapproved
Epithalon 10 mg/mL MDV (5 mL)	3	Category 2 > April 2026 > Unapproved
GHK-CU 10MG/ML MDV (5mL)	16	Category 2 > April 2026 > Unapproved
Humanin 1mg/mL MDV (10mL)	1	Unapproved
Ibutamoren (MK-677) 25mg Oral Capsules	2	Category 2
IGF-LR3 200mcg/mL MDV (1mg - 5mL)	1	Biologic
KPV 500MCG ORAL CAPSULES	1	Category 2 > April 2026 > Unapproved
LL-37 1MG/ML MDV (5mL)	1	Category 2 > April 2026 > Unapproved
MOTS-C 10 MG/ML MDV (5ML)	5	Category 2 > April 2026 > Unapproved
Pinealon 4mg/mL MDV (5mL)	1	Unapproved
SELANK 10MG/ML NASAL SPRAY (5ML)	3	Category 2 > April 2026 > Unapproved
SELANK 7.5MG/ML NASAL SPRAY (5ML)	3	Category 2 > April 2026 > Unapproved
SEMAX 10MG/ML NASAL SPRAY (5ML)	2	Category 2 > April 2026 > Unapproved
SEMAX 7.5MG/mL NASAL SPRAY (5ML)	3	Category 2 > April 2026 > Unapproved
Sermorelin/Ipamorelin 3 mg - 2 mg/mL MDV (5 mL)	4	Unapproved
SS-31 40MG/ML MDV (5ML)	5	Category 2 > April 2026 > Unapproved
Tesamorelin/Ipamorelin 3mg-0.3mg/mL MDV (10mL)	16	Unapproved (Ipamorelin)
THYMOSIN ALPHA-1 3MG/ML MDV (5ML)	6	Category 2 > April 2026 > Unapproved
THYMOSIN BETA-4 3MG/ML MDV (5 mL)	8	Category 2 > April 2026 > Unapproved
Thymosin Beta-4 6mg/mL MDV (5mL)	1	Category 2 > April 2026 > Unapproved
	177	